Shi, Yu
Gao, Weina
Lytle, Nikki K.
Huang, Peiwu
Yuan, Xiao
Dann, Amanda M.
Ridinger-Saison, Maya
DelGiorno, Kathleen E.
Antal, Corina E.
Liang, Gaoyang
Atkins, Annette R.
Erikson, Galina
Sun, Huaiyu
Meisenhelder, Jill
Terenziani, Elena
Woo, Gyunghwi
Fang, Linjing
Santisakultarm, Thom P.
Manor, Uri
Xu, Ruilian
Becerra, Carlos R.
Borazanci, Erkut
Von Hoff, Daniel D.
Grandgenett, Paul M.
Hollingsworth, Michael A.
Leblanc, Mathias
Umetsu, Sarah E.
Collisson, Eric A.
Scadeng, Miriam
Lowy, Andrew M.
Donahue, Timothy R.
Reya, Tannishtha
Downes, Michael
Evans, Ronald M.
Wahl, Geoffrey M.
Pawson, Tony
Tian, Ruijun
Hunter, Tony
Article History
Received: 23 June 2017
Accepted: 14 March 2019
First Online: 17 April 2019
Change Date: 30 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-021-04176-w
Competing interests
: E.B. is a scientific advisor to Fujifilm, Ipsen and Corcept. D.D.V.H. is an employee of McKesson, a co-founder of Stromatis Pharma and Systems Oncology, and a shareholder of McKesson, Medtronic, CerRx, SynDevRx, UnitedHealthare, Anthem, Capella Therapeutics and Cell Therapeutics. D.D.V.H. is a scientific advisor to DNAtrix, Esperance, Five Prime, Imaging Endpoints, Immoduon, Insys, Medical Prognosis Institute, miRNA Therapeutics, Senhwa Biosciences, Tolero, Trovagene, Alpha Cancer Techologies, Arvinas, Bellicum, CanBas, Horizon Discovery, Innate, Lixte Biotechnology, Oncolyze, RenovoRx, TD2, AADI, Aptose Biosciences, BiolineRx, CV6, CytomX, EMD Serono, Evelo, Fujifilm, Histogen, Intezyne, Kalos, Kura, Phosplatin, SOTIO, Strategia, Sun Biopharma, Synergene, Systems Imagination, 7 Hills, Actinium, Aduro Biotech, ARMO BioSciences, Cancer Prevention Pharmaceuticals, Defined Health, Geistlich Pharma, HUYA Bioscience, Immunophotonics, Novocure, ARIAD, Boston Biomedical, Corrona, Forma, Genzada, L.E.A.F., Oncology Venture, Reflexion Medical, TP Therapeutics, Verily, Athenex, Fate, FibroGen, Jounce Therapeutics, Samus Therapeutics, Sumitomo Dainippon, Aeglea Biotherapeutics, 2X Oncology, Innokeys, Novita, NuCana BioMed, Araxes, Ipsen, SciClone, TargaGenix, Trans Med, Veana Therapeutics, Biospecifics Technologies, Riptide Bioscience, Vicus Therapeutics, Codiak Biosciences, Decoy Biosystems, OSI, Agenus, Globe Life Science, Kelun–Klus Pharma, RadImmune, Samumed, SOBI, Adicet Bio, BioXCel Therapeutics, Bryologyx, Celgene, Helix BioPharma, Sirnoamics, AiMed Bio, Boston Scientific, Corcept, Erimos and Gimbal.